Biocardia announces first patient treated in cardiamp cell therapy trial for chronic myocardial ischemia

San carlos, calif., oct. 21, 2021 (globe newswire) -- biocardia®, inc.  [nasdaq: bcda] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first patient in its phase iii pivotal cardiamp cell therapy chronic myocardial ischemia trial for patients with no option chronic myocardial ischemia with refractory angina. these patients experience frequent angina (chest pain) attacks that are uncontrolled by optimal drug therapy but are not suitable candidates for stent placement or bypass surgery, leaving them with no therapeutic options.
BCDA Ratings Summary
BCDA Quant Ranking